Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASPIAN first-line extensive-stage small-cell lung cancer study
2016-001203-23Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab, etoposide, carboplatin and cisplatin in small cell lung cancer (SCLC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall survival. Started Jan 2017; status: completed.
02
Drugs
durvalumabtremelimumabetoposidecarboplatincisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2016-001203-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001203-23.